NCT00074646已完成1 期
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 2
研究概览
简要总结
Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with glioblastoma multiforme (GBM), gliosarcoma, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), malignant glioma/astrocytoma NOS (not otherwise specified). Also included will be radiographically diagnosed infiltrating brain stem gliomas not amenable to biopsy. Other CNS tumor histologies will not be eligible for this trial.
- •Patients must have shown either evidence for tumor recurrence or progression by CT or (preferably) MRI scan performed within 21 days prior to registration or had biopsy proven recurrent glioma within the last 12 weeks prior to enrollment (in order to allow the enrollment of patients with recurrent gliomas who have undergone a complete radiographic resection and now have no radiographic evaluable disease)
- •Patients having undergone recent resection of a recurrent or progressive tumor will be eligible two weeks after surgery.
- •Patient must have failed prior radiation therapy and must have an interval of greater than or equal to 2 weeks from the completion of radiation therapy to study entry.
- •All patients must sign an informed consent, or if cognitively impaired, their assigned DPA, indicating that they are aware of the investigational nature of this study.
- •Patients must be > 18 years old, and must have a life expectancy > 8 weeks.
- •Patients must have a Karnofsky performance status of >
- •Additionally, patients must be at least 6 weeks from nitrosoureas, 4 weeks from temozolomide or carboplatin, 3 weeks from procarbazine, and 2 weeks from last vincristine administration. Patients must be at least 4 weeks from other cytotoxic therapies not listed above and 2 weeks for non-cytotoxic agents (e.g., interferon, tamoxifen).
- •Patients must have adequate bone marrow function (granulocyte count >= 1500/mm3, platelet count of > 100,000/mm3, and hemoglobin > 8 gm%), adequate liver function (total bilirubin <= 1.5 mg/dL, AST/ALT <= 2 x ULN), and adequate renal function (creatinine <= 1.5 mg/dL or creatinine clearance > 60 cc/min) before starting therapy. These tests must be performed within 14 days prior to registration. Eligibility level for hemoglobin may be reached by transfusion. Eligibility level for platelets may not be reached by transfusion.
- •Patients must either not be receiving steroids, or be on a stable dose of steroids for at least five days prior to registration.
- •Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix) are ineligible, unless they are in complete remission and off all therapy for that disease for a minimum of 3 years.
- •Patients must not be pregnant or nursing, and all patients (both men and women) must be willing to practice birth control during and for 2 months after treatment with CC-
- •Women of childbearing potential (WCBP) who are sexually active must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).
- •Patients must be able to swallow capsules whole.
排除标准
- •Patients who, in the view of the treating physician, have significant active cardiac, hepatic, renal, or psychiatric diseases that would significantly increase the risk of using CC-8490 are ineligible.
- •Concurrent use of other standard chemotherapeutics or investigative agents.
- •Pregnant or lactating females.
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study, obscures the evaluation of toxicity or alters drug metabolism.
- •Use of other experimental study drug within 28 days of registration.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
CC-8490 in Treating Patients With Recurrent or Refractory High-Grade GliomasBrain and Central Nervous System TumorsNCT00074243National Cancer Institute (NCI)
已完成
2 期
CCI-779 in Treating Patients With Recurrent Glioblastoma MultiformeAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain TumorNCT00016328National Cancer Institute (NCI)33
已完成
1 期
Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline GliomasBrain and Central Nervous System TumorsNCT03696355St. Jude Children's Research Hospital27
招募中
1 期
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN AmplificationsGliomaMedulloblastomaEpendymomaGlioblastomaNCT06161519National Cancer Institute (NCI)146
进行中（未招募）
1 期
Study of DSP-0390 in Patients With Recurrent High-Grade GliomaHigh Grade GliomaGlioblastoma MultiformeNCT05023551Sumitomo Pharma America, Inc.39